Skip to main content
Erschienen in: Clinical Rheumatology 4/2021

14.11.2020 | COVID-19 | Brief Report Zur Zeit gratis

COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort

verfasst von: Greta Pellegrino, Davide Mohammad Reza Beigi, Carlotta Angelelli, Katia Stefanantoni, Marius Cadar, Silvia Mancuso, Fabrizio Conti, Valeria Riccieri

Erschienen in: Clinical Rheumatology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

The outbreak of SARS-CoV-2 has changed the habits and lives of people worldwide. Patients affected by systemic sclerosis (SSc) experienced constant fear because of their immunocompromised status. The aim of this study was to investigate the prevalence of SARS-CoV-2 infection and to analyze the lifestyle changes in a single-center cohort of SSc patients and if these changes were more severe than in the general population. During the Italian lockdown, we supplied two surveys to our 184 SSc patients. In the first one, filled by 110 patients, we asked if SARS-CoV-2 had infected them or if they experienced signs and symptoms consistent with COVID-19. The second survey, performed by 79 SSc patients and 63 healthy subjects, included questions about the lifestyle adopted during this specific period. Among our patients, COVID-19 was diagnosed only in one case, while three other subjects reported signs and symptoms suggestive for the disease. Regarding the second survey, our patients greatly changed their lifestyle during the pandemic, adopting more restrictive isolation measures, because of their awareness of frailty. To date, we do not dispose of enough data to speculate about the risk of COVID-19 among immunocompromised patients, although in our SSc patients their frailty seems to have been their shelter. Pending more accurate epidemiological studies, it is essential to share as much data as possible to better understand the impact of COVID-19 on SSc patients’ health.
Key points
• The lifestyle adopted by SSc patients during the first months of COVID-19 pandemic was characterized by more stringent isolation rules than general population.
• The prudential behavior of patients with SSc during Italian lockdown should be considered as a possible bias when analyzing the risk of SARS-CoV-2 disease in these subjects, as well as a protective factor against infection.
Literatur
1.
Zurück zum Zitat Di Franco M, Lucchino B, Spaziante M, Iannucelli C, Valesini G, Iaiani G (2017) Lung infections in systemic rheumatic disease: focus on opportunistic infections. Int J Mol Sci 18:293CrossRef Di Franco M, Lucchino B, Spaziante M, Iannucelli C, Valesini G, Iaiani G (2017) Lung infections in systemic rheumatic disease: focus on opportunistic infections. Int J Mol Sci 18:293CrossRef
2.
Zurück zum Zitat Del Papa N, Sambataro G, Minniti A, Pignataro F, and Caporali R (2020) Novel coronavirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev; 102558 Del Papa N, Sambataro G, Minniti A, Pignataro F, and Caporali R (2020) Novel coronavirus disease 2019 (COVID-19) epidemic: what are the risks for systemic sclerosis patients? Autoimmun Rev; 102558
3.
Zurück zum Zitat Orlandi M, Lepri G, Bruni C, Wang Y, Bartoloni A, Zammarchi L, Cometi L, Guiducci S, Matucci-Cerinic M, Bellando-Randone S (2020) The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol 39(7):2043–2047CrossRef Orlandi M, Lepri G, Bruni C, Wang Y, Bartoloni A, Zammarchi L, Cometi L, Guiducci S, Matucci-Cerinic M, Bellando-Randone S (2020) The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol 39(7):2043–2047CrossRef
4.
Zurück zum Zitat Van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747CrossRef Van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747CrossRef
5.
Zurück zum Zitat Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP (2020) Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients. Scand J Rheumatol:1–2. https://doi.org/10.1080/03009742.2020.1800083 Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP (2020) Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients. Scand J Rheumatol:1–2. https://​doi.​org/​10.​1080/​03009742.​2020.​1800083
6.
Zurück zum Zitat Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F, Bindoli S, Gatto M, Felicetti M, Ortolan A, Campaniello D, Larosa M, Lorenzin M, Ramonda R, Sfriso P, Schiavon F, Iaccarino L, Doria A (2020) SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun 112:102502. https://doi.org/10.1016/j.jaut.2020.102502CrossRefPubMedPubMedCentral Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, Cozzi G, Depascale R, Zanatta E, Gasparotto M, Benvenuti F, Bindoli S, Gatto M, Felicetti M, Ortolan A, Campaniello D, Larosa M, Lorenzin M, Ramonda R, Sfriso P, Schiavon F, Iaccarino L, Doria A (2020) SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun 112:102502. https://​doi.​org/​10.​1016/​j.​jaut.​2020.​102502CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco M (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667–668CrossRef Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco M (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79(5):667–668CrossRef
9.
Zurück zum Zitat Bozzalla-Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L (2020) COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 79:1382–1383CrossRef Bozzalla-Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L (2020) COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 79:1382–1383CrossRef
10.
Zurück zum Zitat Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L (2020) Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis 79:1252–1253CrossRef Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L (2020) Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis 79:1252–1253CrossRef
11.
Zurück zum Zitat Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A, on behalf of the COVID-19 & ASD Italian Study Group (2020) COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. Ann Rheum Dis 39(11):3195–3204 Ferri C, Giuggioli D, Raimondo V, Fallahi P, Antonelli A, on behalf of the COVID-19 & ASD Italian Study Group (2020) COVID-19 in Italian patients with rheumatic autoimmune systemic diseases. Ann Rheum Dis 39(11):3195–3204
13.
Zurück zum Zitat Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, de Paulis A, Denton CP, Distler O, Fox D, Furst DE, Jhanna D, Krieg T, Kuwana M, Lee EB, Li M, Pillai S, Wang Y, Zeng X, Taliani G (2020) Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 79(6):724–726CrossRef Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, de Paulis A, Denton CP, Distler O, Fox D, Furst DE, Jhanna D, Krieg T, Kuwana M, Lee EB, Li M, Pillai S, Wang Y, Zeng X, Taliani G (2020) Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Ann Rheum Dis 79(6):724–726CrossRef
14.
Zurück zum Zitat Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95CrossRef Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95CrossRef
15.
Zurück zum Zitat Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323(16):1574–1581CrossRef Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A (2020) Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323(16):1574–1581CrossRef
16.
Zurück zum Zitat Doyle TJ, Dellaripa PF (2017) Lung manifestations in the rheumatic diseases. Chest 152(6):1283–1295CrossRef Doyle TJ, Dellaripa PF (2017) Lung manifestations in the rheumatic diseases. Chest 152(6):1283–1295CrossRef
17.
Zurück zum Zitat Gianfrancesco MA, Hyrich KH, Gossec L, Stranfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J, the COVID-19 Global Rheumatology Alliance Steering Committee (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology Alliance provider registries. Lancet Rheumatol 2(5):e250–e253CrossRef Gianfrancesco MA, Hyrich KH, Gossec L, Stranfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J, the COVID-19 Global Rheumatology Alliance Steering Committee (2020) Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology Alliance provider registries. Lancet Rheumatol 2(5):e250–e253CrossRef
19.
Zurück zum Zitat Spinelli FR, Ceccarelli F, Di Franco M, Conti F (2020) To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis 79(5):666–667CrossRef Spinelli FR, Ceccarelli F, Di Franco M, Conti F (2020) To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis 79(5):666–667CrossRef
20.
Zurück zum Zitat Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, Maurer B, Distler O (2020) COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 79:668–669CrossRef Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, Maurer B, Distler O (2020) COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 79:668–669CrossRef
21.
Zurück zum Zitat Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D’Alessandro R, Cantarini L, Frediani B (2020) COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis:annrheumdis-2020-217681. https://doi.org/10.1136/annrheumdis-2020-217681 Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D’Alessandro R, Cantarini L, Frediani B (2020) COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis:annrheumdis-2020-217681. https://​doi.​org/​10.​1136/​annrheumdis-2020-217681
Metadaten
Titel
COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort
verfasst von
Greta Pellegrino
Davide Mohammad Reza Beigi
Carlotta Angelelli
Katia Stefanantoni
Marius Cadar
Silvia Mancuso
Fabrizio Conti
Valeria Riccieri
Publikationsdatum
14.11.2020
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
Clinical Rheumatology / Ausgabe 4/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05504-7

Weitere Artikel der Ausgabe 4/2021

Clinical Rheumatology 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Nierenultraschall: Tipps vom Profi

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

„KI sieht, was wir nicht sehen“

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.